Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid

Sevim Cakar; Gulin Eren; Cahit Baris Erdur; Mehmet Onder; Safak Pelek; Sedef Alpdogan; Duygu Demirtas; Cigdem Omur Ecevit; Ozlem Bekem

doi:10.3390/children11121553

Back

Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid

Journal article

Peer reviewed

Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid

Sevim Cakar, Gulin Eren, Cahit Baris Erdur, Mehmet Onder, Safak Pelek, Sedef Alpdogan, Duygu Demirtas, Cigdem Omur Ecevit and Ozlem Bekem

Children (Basel), Vol.11(12), p.1553

12/01/2024

DOI: 10.3390/children11121553

PMID: 39767982

Files and links (1)

url

https://doi.org/10.3390/children11121553View

Published (Version of record) Open Access

Abstract

Background: Cholelithiasis is a rare disease in infants, and there is limited data on its risk factors and management. Objectives: To evaluate the risk factors, management, and response to medical treatment of cholelithiasis in infants. Methods: Infants diagnosed with cholelithiasis by ultrasound between 2018 and 2023 were retrospectively analyzed. Details of patient history, imaging findings, current symptoms, and treatments were reviewed. Results: Over 5 years, 98 infants were diagnosed with cholelithiasis. Thirty-three (33.7%) were girls, and the most common risk factors were the use of cephalosporin antibiotic therapy in 46.9%, sepsis in 30.6%, total parenteral nutrition in 29.6%, prematurity in 27.6%, congenital heart disease in 18.4%, and genetic disease (Down syndrome diagnosis in seven patients) in 16.3%. Only fifteen patients (15.3%) were symptomatic. Ursodeoxycholic acid (UDCA) treatment was given to 90.8% of patients, but nine of them used it for a short period or irregularly, and regular users were 81.6%. Gallstones disappeared in 46 patients (46.9%), including 14 (30.4%) without using UDCA regularly. The response rate to UDCA treatment was lower in preterm infants (p = 0.004). Gallstone resolution was higher in the nonusers, 14/18 (77.8%) versus 32/79 (40.5%) (p = 0.03). Acute cholecystitis was observed in only four patients; no other complications were noted. No infant required surgical or endoscopic treatment. Conclusions: UDCA should not be used routinely in children, especially infants, except in symptomatic children with a contraindication to surgery or to reduce clinical symptoms. In the absence of symptoms, patients may be monitored clinically.

Life Sciences & Biomedicine

Pediatrics

Science & Technology

Details

Title: Subtitle: Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid
Creators: Sevim Cakar - Dokuz Eylül University
Gulin Eren - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Cahit Baris Erdur - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Mehmet Onder - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Safak Pelek - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Sedef Alpdogan - Ege University
Duygu Demirtas - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Cigdem Omur Ecevit - Univ Hlth Sci, Dr Behcet Uz Childrens Hosp, Dept Pediat, Div Pediat Gastroenterol, TR-35210 Izmir, Turkiye
Ozlem Bekem - Dr. Behçet Uz Çocuk Hastalıkları Hastanesi
Resource Type: Journal article
Publication Details: Children (Basel), Vol.11(12), p.1553
DOI: 10.3390/children11121553
PMID: 39767982
ISSN: 2227-9067
eISSN: 2227-9067
Publisher: Mdpi
Number of pages: 6
Language: English
Date published: 12/01/2024
Academic Unit: Stead Family Department of Pediatrics; Gastroenterology, Hepatology, Pancreatology, and Nutrition
Record Identifier: 9985217819702771

Metrics

1 Record Views

2 Times Cited - Web of Science